997 resultados para département 35.
Resumo:
Adolf Kober
Resumo:
BACKGROUND Kidney recipients maintaining a prolonged allograft survival in the absence of immunosuppressive drugs and without evidence of rejection are supposed to be exceptional. The ERA-EDTA-DESCARTES working group together with Nantes University launched a European-wide survey to identify new patients, describe them and estimate their frequency for the first time. METHODS Seventeen coordinators distributed a questionnaire in 256 transplant centres and 28 countries in order to report as many 'operationally tolerant' patients (TOL; defined as having a serum creatinine <1.7 mg/dL and proteinuria <1 g/day or g/g creatinine despite at least 1 year without any immunosuppressive drug) and 'almost tolerant' patients (minimally immunosuppressed patients (MIS) receiving low-dose steroids) as possible. We reported their number and the total number of kidney transplants performed at each centre to calculate their frequency. RESULTS One hundred and forty-seven questionnaires were returned and we identified 66 TOL (61 with complete data) and 34 MIS patients. Of the 61 TOL patients, 26 were previously described by the Nantes group and 35 new patients are presented here. Most of them were noncompliant patients. At data collection, 31/35 patients were alive and 22/31 still TOL. For the remaining 9/31, 2 were restarted on immunosuppressive drugs and 7 had rising creatinine of whom 3 resumed dialysis. Considering all patients, 10-year death-censored graft survival post-immunosuppression weaning reached 85% in TOL patients and 100% in MIS patients. With 218 913 kidney recipients surveyed, cumulative incidences of operational tolerance and almost tolerance were estimated at 3 and 1.5 per 10 000 kidney recipients, respectively. CONCLUSIONS In kidney transplantation, operational tolerance and almost tolerance are infrequent findings associated with excellent long-term death-censored graft survival.
Resumo:
Welsch (Projektbearbeiter): Siege der ungarischen Revolutionsarmee bei Waitzen und Nagy-Salló (9. und 19. April 1849); der Donaulauf von Komorn bis Waitzen befindet sich in ungarischer Hand. Vorbereitung des österreichischen Rückzuges aus Pest
Resumo:
Welsch (Projektbearbeiter): Verurteilung des Doktors der Pharmazie Pallucci sowie des Berufslosen Brzyiemski zu dreijähriger Festungshaft resp. vierjähriger Zwangsarbeit wegen Aufruhrs
Resumo:
PURPOSE Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS Two hundred seventy patients with untreated, relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of rituximab monotherapy in weekly intervals (375 mg/m(2)). Patients achieving at least a partial response were randomly assigned to receive maintenance therapy with one infusion of rituximab every 2 months, either on a short-term schedule (four administrations) or a long-term schedule (maximum of 5 years or until disease progression or unacceptable toxicity). The primary end point was event-free survival (EFS). Progression-free survival, overall survival (OS), and toxicity were secondary end points. Comparisons between the two arms were performed using the log-rank test for survival end points. RESULTS One hundred sixty-five patients were randomly assigned to the short-term (n = 82) or long-term (n = 83) maintenance arms. Because of the low event rate, the final analysis was performed after 95 events had occurred, which was before the targeted event number of 99 had been reached. At a median follow-up period of 6.4 years, the median EFS was 3.4 years (95% CI, 2.1 to 5.3) in the short-term arm and 5.3 years (95% CI, 3.5 to not available) in the long-term arm (P = .14). Patients in the long-term arm experienced more adverse effects than did those in the short-term arm, with 76% v 50% of patients with at least one adverse event (P < .001), five versus one patient with grade 3 and 4 infections, and three versus zero patients discontinuing treatment because of unacceptable toxicity, respectively. There was no difference in OS between the two groups. CONCLUSION Long-term rituximab maintenance therapy does not improve EFS, which was the primary end point of this trial, or OS, and was associated with increased toxicity.
Hs. Rothschild 4° 35 - Katalog der Bibliothek des Musikdirektors Dr. H. Henkel zu Frankfurt am Main
Resumo:
Vorbesitzer: Dr. H. Henkel; Freiherrlich Carl von Rothschild'sche Bibliothek Frankfurt am Main (Bibliothek für Neuere Sprachen und Musik, Frankfurt am Main); alte Signatur: Hs in 4° 35; Akzessionsnummer: 20229
Resumo:
Fürchtegott Christian Fulda
Resumo:
Bernhard Heller
Resumo:
Wilhelm Bacher
Resumo:
Wilhelm Bacher
Resumo:
Digitalisat des Mikrofilms (MF 4430)
Resumo:
Vorbesitzer: Kloster Herrenleichnam Köln; Georg Kloß; Johann Friedrich Boehmer
Resumo:
Vorbesitzer: Johannes Mushunt de Fulda; Bartholomaeusstift Frankfurt am Main